Roivant Sciences Stock
Biopharmaceutical company
About Roivant Sciences Stock
Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. It is a unique biopharmaceutical company with world-class drug development experts working across multiple clinical and functional areas.
Investors
Dexcel Pharma
Founders Fund
Lyft, Spotify, Airbnb, SpaceX, Palantir Technologies, Stripe, Wish, Compass, Just, Flexport
Novaquest Capital Management
QVT Financial
RTW Investments LLC
SoftBank Vision Fund
Grab, DoorDash, View, Flexport, Rappi, Katerra, Nuro, Automation Anywhere, WeWork, Cohesity
Viking Global Investors
Moderna Therapeutics, Impossible Foods, Ginkgo Bioworks, Adaptive Biotechnologies, Apeel Sciences, Druva, Credit Karma, Color, PROCEPT BioRobotics, Talkdesk
Funding History
| November 2018 | $200M |
|---|---|
| August 2017 | $1.1B |
| July 2016 | $500M |
| May 2014 | $93.0M |
Management
Co-Founder & Chief Executive Officer
Vivek Ramaswamy
Chief Information Officer
Daniel Rothman
Chief Financial Officer
Matthew Gline
Chief Accounting Officer
Rakhi Kumar
Press
ThePharmaLetter - Oct, 31 2019
globenewswire - Sep, 6 2019
fiercebiotech - Feb, 14 2019
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Roivant Sciences or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
